Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Tocris Bioscience™ ABT 199

Click to view available options
Quantity:
10 mg
50 mg
Description
ABT 199 is a selective, high affinity Bcl-2 inhibitor (Ki < 0.010 nM). Exhibits >4800-fold selectivity for Bcl-2 over Bcl-xL and Bcl-w, and displays no measurable activity at Mcl-1 (Ki > 444 nM). Potently induces apoptosis in FL5.12-BCL-2 cells (EC50 = 261 nM) and reduces tumor burden in chronic lymphocytic leukemia (CLL) primary samples (EC50 = 3 nM). Shows reduced toxicity to platelets compared to similar compounds. Enhances efficacy of clinically relevant chemotherapy and immunotherapy drugs. Orally bioavailable. Exhibits binding to SARS-CoV-2 3C-like protease (3CLpro) active site in a virtual screen. ABT 199 reverses oxidative phosphorylation in acute myeloid leukemia cells (AML), in vitro and in vivo.
Specifications
Specifications
Chemical Name or Material | 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2 H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1 H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide |
CAS | 1257044-40-8 |
Synonym | GDC-0199 |
Quantity | 10 mg |
Target | Bcl-2 Family Inhibitors |
Molecular Formula | C45H50ClN7O7S |
Formula Weight | 868.45 |
Product Type | Inhibitor |
Purity | 98% |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction